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sion was used to estimate the odds ratio of the outcome events for patients whose 
treatment in the week before event date included statins and BBs as compared to 
patients whose treatment included statins and other BPLD(s). Results: Patients on 
statins and BBs showed substantially higher risks for cardiovascular death (OR= 2.12, 
95%CI: 1.81–2.49), all-cause death (OR= 1.64, 95%CI: 1.49–1.81), CVD events (OR= 1.96, 
95%CI: 1.80–2.12) and hospitalization for CVD (OR= 1.99, 95%CI: 1.82–2.17) as com-
pared to patients on statins and other BPLDs. Sensitivity analyses suggest that this 
higher risk is not due to differences in prescription patterns based on perceived 
disease severity (indication bias). ConClusions: In elderly hypertensive patients, 
the concurrent use of statins and BBs is associated with less effective primary 
prevention in comparison to the use of statins in combination with other BPLDs. 
Consequently, the difference observed in the efficacy of different classes of BPLDs 
in elderly populations in primary prevention remains significant in the subpopula-
tion receiving statins. Further studies should be conducted to confirm this finding.
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objeCtives: We examined the potential clinical implications of prescribing pat-
terns of generic statins within 11 Latin American markets (LA11). In LA11, generic 
versions of pravastatin, simvastatin and atorvastatin are available, however, each 
statin has a different LDL-cholesterol (LDL-C) lowering efficacy that may ulti-
mately result in differences in the incidence of CV events. 2011 LA11 prescription 
data indicate that statins are prescribed at doses that do not yield equivalent 
LDL-C lowering. Thus we calculated the weighted average daily doses (WADDs) 
of pravastatin, simvastatin and atorvastatin within LA11 and estimated the aver-
age LDL lowering with each statin, and the incidence of CV events. Methods: 
The WADDs of prescribed simvastatin, pravastatin and atorvastatin in LA11 were 
derived from IMS data. The LDL-C modifying potencies of the WADDs were inter-
polated from dose response curves from Nicholls et al (Am J Cardiol, 2010), and 
Law et al (BMJ, 2003). The relationship between LDL-C reduction and the result-
ant impact on cardiovascular events was derived from the Cholesterol Treatment 
Trialists’ Collaboration (CTTC, Lancet 2010), where a 1mmol/L reduction in 
LDL-C, translated to a 22% reduction in major cardiovascular events. Results: 
Across LA11, the WADDs for pravastatin, simvastatin and atorvastatin were 
24.9mg, 22.4mg and 20.6mg, respectively. The corresponding reductions in LDL-C 
at these doses were estimated to be 25.0%, 33.4% and 40.6%. Assuming a pre-
treatment LDL-C of 4.0mmol/L, these lipid changes would lead to reductions 
in the risk of a major coronary/stroke event of 22.0%, 29.4% and 35.8%, respec-
tively. ConClusions: At currently prescribed WADDs in LA11, the real world 
use of atorvastatin provides a superior reduction in LDL-C to either simvastatin 
or pravastatin, and hence would be expected to result in a greater reduction in 
cardiovascular events.
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objeCtives: Diuretics are drugs of first choice in the treatment of hypertension. 
The aim of this study was to analyze the consumption of diuretics in Serbia in the 
period from 2006 to 2010 year. Methods: The data about the use of drugs were 
taken from the Agency for Drugs and Medical Devices of the Serbia. Results: The 
use of diuretics during the observed period in Serbia is quite small and it ranged 
from 5 to 6% of the total consumption of all drugs from the C group. Furosemide 
was the most frequently used diuretic. In the five year period furosemide con-
sumption ranged from 33-55% of the total consumption of all diuretics. The second 
largest consupmtion during first four years of the study was that of indapamide. 
Indapamide consumption in the fifth year was at the fourth position. At the third 
position in drug consumption in the first four years was hydrochlorothiazide. Use 
of hydrochlorothiazide in 2010 took second place. Spironolactone has occupied 
the fourth position in the first four years. During the last years of the period 
spironolactone occupied the third position. Consumption of all other diuretics 
was small and it was only a few percent of the total consumption of all diuret-
ics. ConClusions: In Serbia, in the observed period, consumption of diuterics 
is two to three times lower in comparison with the consumption of diuretics 
in Norway and Finland. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, pro-
ject no 41012.
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objeCtives: Drugs of first choice in the treatment of hypertension are: β -blockers, 
tiazide diuretics, ACE inhibitors, angiotensin receptor inhibitors and Ca chan-
nel blockers. The aim of this study was to analyze the consumption of antihy-
pertensive drugs in Serbia in the period from 2007 to 2011 year. Methods: The 
data about the use of drugs were taken from the Agency for Drugs and Medical 
Devices of the Serbia. Results: The use of diuretics during the observed period 
in Serbia is quite small and it ranged from 5 to 6% of the total consumption of all 
drugs from the C group. Consumption of β -blockers was around 12% during all 5 
years. Consumption of calcium channel blockers was less than 12% of the total 
consumption of all drugs from group C in the first 2 years of the observed period. 
However, consumption of such drugs in the last 3 years growing over 18% of the 
tors of a difficult procedure. ConClusions: Factors influencing the difficulty of 
an extraction procedure are the number of leads, the presence of screw leads, the 
presence of dual-coil tachy leads, the years since the oldest lead was implanted and 
the absence of leads with vegetation.
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objeCtivos: El Euroscore(EU) es el modelo predictivo más usado en cirugía cardi-
aca; sin embargo, sobreestima el riesgo y la información necesaria para calcularlo 
no siempre está disponible. Este estudio fue diseñado para: 1). Definir si adicio-
nar el valor preoperatorio de hemoglobina (HB), péptido natriurético tipo B(BNP) o 
ambos, al EU, mejoran su capacidad predictiva sobre morbimortalidad a 6 meses 
de seguimiento postoperatorio en toda la muestra y en los pacientes diabéticos; y 
2). Evaluar la utilidad de EU en nuestro medio. MetodologíAs: Se incluyeron 492 
pacientes quirúrgicos cardiacos. Se comparò directamente la capacidad predictiva 
de BNP y/o HB vs EU. Luego se evaluó en que tanto la incorporación de BNP y/o HB 
al EU, adicionaron en términos de lograr mejor discriminación. Para cada uno de 
los desenlaces se construyeron y compararon curvas ROC. ResultAdos: Sobre 
mortalidad, BNP o HB no adicionan capacidad predictiva al EU ni en la muestra 
global ni en diabéticos. La mortalidad intrahospitalaria fue mejor discriminada 
por EU aislado: área bajo la curva ROC (ABC-ROC): 0.83(IC95%0.75-0.92) y a 6 meses, 
ABC-ROC 0.73 (IC95% 0.64-0.83); en pacientes diabéticos, ABC-ROC 0.95 (IC95%0.91-
1.00) para mortalidad intrahospitalaria y a 6 meses, ABC-ROC 0.84 (IC95% 0.74-0.98). 
La discriminación obtenida con BNP fue buena para bajo gasto cardiaco: ABC-ROC, 
0.72 (IC95% 0.67-0.77); e insuficiencia renal aguda ABC-ROC 0.75 (IC95% 0.76-0.84). 
Los mejores predictores de transfusión fueron EU+HB ó BNP+HB. EU mostró buena 
capacidad predictiva (ABC-ROC≥ 0.70) sobre morbilidad combinada, estancia pro-
longada en cuidado intensivo, bajo gasto cardiaco e insuficiencia renal y a 6 meses 
en la discriminación de evento cerebrovascular, tanto en el grupo total como en 
diabéticos. ConClusiones: La capacidad discriminatoria de EU para mortalidad 
en nuestro medio es muy buena, especialmente en diabéticos. BNP o HB no adi-
cionan capacidad predictiva. En la mayor parte de los desenlaces de morbilidad la 
discriminación obtenida con BNP aislado es comparable a EU.
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objeCtives: To compare changes in blood pressure after 8 weeks of therapy 
between a fixed-dose combination (FDC) of amlodipine/losartan and amlodipine/
valsartan using a network meta-analysis because there are no trials directly compar-
ing amlodipine/losartan to amlodipine/valsartan. Methods: A systematic search 
identified six randomized controlled trials of study FDCs and their component 
monotherapies; 3 included amlodipine/losartan and 3 included amlodipine/vals-
artan. Conventional fixed-effects methods were used to conduct the comparisons. 
The change in sitting diastolic and systolic blood pressure (sitDBP, sitSBP) at 8 weeks 
post-randomization was the primary and secondary effect measures. Results: 
Amlodipine/losartan 5/50 mg produced greater reductions in sitDBP (-1.27 mmHg, 
95% confidence interval (CI) -5.7 - 2.2) and sitSBP (-3.7 mmHg, 95% CI -9.0 - 2.9) than 
amlodipine/valsartan 5/80 mg. Amlodipine/losartan 5/100 mg produced a greater 
reduction in sitDBP (-0.45 mmHg, 95% CI -3.7 - 2.7) than amlodipine/valsartan 5/160 
mg while amlodipine/valsartan 5/160 mg had a greater reduction in sitSBP (0.2 
mmHg, 95% CI -6.2 - 6.0) than amlodipine/losartan 5/100 mg. The confidence of supe-
rior antihypertensive efficacy for COZAAR XQ 5/50 mg than amlodipine/valsartan 
5/80 mg is 77% for sitDBP and 89% for sitSBP, while the confidence of greater efficacy 
for amlodipine/losartan 5/100 mg than amlodipine/valsartan 5/160 mg is 61% for 
sitDBP and 48% for sitSBP. With 95% CI, the reduction difference in sitDBP and sitSBP 
between amlodipine/valsartan 5/80 mg and amlodipine/losartan 5/100 mg is not 
expected to exceed 1.6 mmHg and 1.26 mmHg, respectively, and not expected to 
exceed 2.31 mmHg and 5.38 mmHg, respectively with amlodipine/valsartan 5/160 
mg versus amlodipine/losartan 5/100 mg. ConClusions: The blood pressure low-
ering effect with amlodipine/losartan and amlodipine/valsartan was comparable. 
The findings from this network metaanalysis do not indicate a potential superiority 
of the reductions realized with amlodipine/valsarta relative to amlodipine/losartan.
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objeCtives: Differences in efficacy of different classes of blood pressure lowering 
drugs (BPLDs) have been observed in elderly primary prevention populations, with 
beta-blockers (BBs) reported to be less efficacious for primary prevention. In this 
study, we assessed if these differences remained significant in patients that use 
statins concurrently. Methods: We conducted a series of population-based nested 
case-control studies using administrative data from 104,023 diagnosed hypertensive 
patients without recent antecedents of diabetes or cardiovascular disease (CVD) in 
the province of Quebec (Canada) between 2000 and 2004. Follow-up ended either 
with an outcome event, or at the end of 2009. Individuals with an outcome event (all-
cause death, CVD event) were considered cases. Controls were matched according 
to age, sex, date of cohort entry, and comorbidity index. Conditional logistic regres-
